GSK is undergoing a significant leadership change as CEO Emma Walmsley steps down, with Luke Miels set to take over in January amidst challenges posed by new US tariffs on pharmaceuticals.
In a surprising move, GSK announced that chief commercial officer Luke Miels will succeed Emma Walmsley as CEO on January 1. Walmsley, who has led the company for nearly nine years, emphasized that 2026 is critical for GSK's future direction, suggesting that new leadership is timely as the company faces external pressures, particularly the recent announcement of 100-percent tariffs on branded drugs by the US government unless companies establish domestic manufacturing.
GSK recently committed to a $30 billion investment in the US over the next five years, a strategic decision that may help mitigate the impact of these tariffs. Miels, a former AstraZeneca executive, expressed confidence in GSK's potential, noting the company's strong prospects as he prepares to assume leadership. Following the announcement, GSK's stock rose by 3.5%, reflecting investor optimism.
Walmsley's tenure included navigating the Covid-19 pandemic and spinning off GSK's consumer healthcare division, now known as Haleon. Her leadership faced scrutiny during the pandemic and in light of legal challenges related to the heartburn drug Zantac. Despite these hurdles, GSK is poised for growth, particularly with increasing sales of cancer treatments, indicating a potentially positive outlook as Miels steps into his new role.